DWP 418

Drug Profile

DWP 418

Alternative Names: DWP-418

Latest Information Update: 22 Jan 2015

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Head and neck cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 22 Jan 2015 No development reported - Phase-I for Head and neck cancer in South Korea (Intratumoural)
  • 22 Jan 2015 No development reported - Phase-I for Malignant melanoma in South Korea (Intratumoural)
  • 22 Jan 2015 No development reported - Phase-I for Solid tumours in South Korea (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top